- Datum24.03.2026
- Uhrzeit18:00 - 19:00 Uhr
- Veranstalter
stock3
Acadia Pharmaceuticals Inc. Chart inkl. Chartanalyse
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate BSX | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
1,40 %
Intraday
0,43 %
1 Woche
-14,66 %
1 Monat
-21,42 %
Seit Jahresbeginn
21,82 %
1 Jahr
15,08 %
3 Jahre
-17,17 %
5 Jahre
3,35 %
10 Jahre
Passender Service zu Acadia Pharmaceuticals Inc.
Webinar zu Acadia Pharmaceuticals Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)13,400-28,350
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Acadia Pharmaceuticals Inc.
Keine Dividenden verfügbar
Termine von Acadia Pharmaceuticals Inc.
- Mai13Acadia Pharmaceuticals Inc.Q1 2026 Earnings Release
- Aug11Acadia Pharmaceuticals Inc.Q2 2026 Earnings Release
- Nov11Acadia Pharmaceuticals Inc.Q3 2026 Earnings Release
Beschreibung
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
